Quest buys clinical lab services of BCL
February 2020—Quest Diagnostics has acquired certain assets of the clinical laboratory services business of Boston Clinical Laboratories, based in Waltham, Mass.
Webinars and Sponsored Roundtables — Register Now
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenters Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
CAP TODAY
FoundationOne CDx gets expanded approval
February 2020—Foundation Medicine has received FDA approval for its FoundationOne CDx to be used as a companion diagnostic for Piqray (alpelisib) in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor–positive, human epidermal growth factor receptor 2–negative, PIK3CA-mutated advanced or metastatic breast cancer following progression on or after an endocrine-based regimen.
FDA approves Tecentriq combo for NSCLC
February 2020—Roche announced FDA approval of Tecentriq (atezolizumab) in combination with chemotherapy (Abraxane [paclitaxel protein-bound; nab-paclitaxel] and carboplatin) for the initial treatment of adults with metastatic non-squamous non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations. The European Commission approved the combination therapy in September.
FDA approves new treatment for HER2+ breast cancer
February 2020—The FDA granted accelerated approval to Enhertu (fam-trastuzumab deruxtecan-nxki) for the treatment of adults with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2–based regimens in the metastatic setting. Enhertu is a human epidermal growth factor receptor 2–directed antibody and topoisomerase inhibitor conjugate.
Siemens launches ELF testing service
February 2020—Siemens Healthineers announced the availability of its Enhanced Liver Fibrosis testing service in the United States, excluding New York State, and Puerto Rico. The testing service is provided by the Siemens Healthcare Laboratory.
Newsbytes
Drone delivery of lab samples: from progress at WakeMed to interest elsewhere
February 2020—After nearly a year of a drone buzzing through the air to deliver specimens from the Raleigh Medical Park surgery center to the laboratory at the flagship Raleigh campus of WakeMed Health and Hospitals a quarter-mile away, WakeMed is looking to expand its drone program.
Clinical Pathology Selected Abstracts
Blood utilization and transfusion reactions in pediatric patients transfused with platelets
February 2020—Even with advances in donor screening and infectious disease testing, the risk of transfusion-transmitted infections continues to be a concern. The FDA has approved a pathogen-reduction system for single-donor platelets, called Intercept Blood System (Cerus Corp.), to treat thrombocytopenic adult and pediatric patients.
Anatomic Pathology Selected Abstracts
DNAJB1-PRKACA fusions in fibrolamellar hepatocellular carcinoma
February 2020—Recently discovered DNAJB1-PRKACA oncogenic fusions have been considered diagnostic for fibrolamellar hepatocellular carcinoma. The authors conducted a study in which they described six pancreatobiliary neoplasms with PRKACA fusions, five of which harbored the DNAJB1-PRKACA fusion.
Molecular Pathology Selected Abstracts
Overall survival rates for lung cancer patients receiving osimertinib
Guidelines recommend testing patients with advanced or metastatic nonsmall cell lung cancer (NSCLC) for epidermal growth factor receptor (EGFR) alterations because targeted treatment with a tyrosine kinase inhibitor (TKI) is available for patients with EGFR exon 19 deletions or L858R point mutations. Osimertinib is a third-generation, irreversible, oral EGFR-TKI that selectively inhibits EGFR-TKI–sensitizing and EGFR p.Thr790Met-resistance mutations.
Olympus Slideview VS200 digital slide scanner
January 2020—Olympus introduced its Slideview VS200 slide scanner, designed to capture high-resolution images for quantitative analysis for brain, cancer, and stem cell research, as well as drug discovery. The scanner uses Olympus X Line objectives, which are designed to deliver flatter images with a wide field of view and no intensity fall off at the periphery, improve numerical aperture, and offer a wider range of chromatic correction.